A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions for the Treatment of Keratoconjunctivitis Sicca in Patients With Chronic Ocular Graft Versus Host Disease

Trial Profile

A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions for the Treatment of Keratoconjunctivitis Sicca in Patients With Chronic Ocular Graft Versus Host Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2016

At a glance

  • Drugs R 348 (Primary)
  • Indications Keratoconjunctivitis sicca
  • Focus Therapeutic Use
  • Acronyms DROPS-2
  • Sponsors Rigel Pharmaceuticals
  • Most Recent Events

    • 12 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 08 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov.
    • 08 Apr 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top